Search
Investors
Careers
Investors
Careers
Company
Our Story
Leadership & Advisors
Pillar News
Distribution Partners
Strategic Partnership
Technology
Products
Portfolio Overview
IVD Products
Solid Tumor Tissue
Liquid Biopsy
Heme
BRCA, HRD, Methylation
InheritRevealâ„¢ Disease
Pharma
Resources
Resource Overview
Webinars and Presentations
Publications
Posters
Contact
Company
Our Story
Leadership & Advisors
Pillar News
Distribution Partners
Strategic Partnership
Technology
Products
Portfolio Overview
IVD Products
Solid Tumor Tissue
Liquid Biopsy
Heme
BRCA, HRD, Methylation
InheritRevealâ„¢ Disease
Pharma
Resources
Resource Overview
Webinars and Presentations
Publications
Posters
Contact
Company
Our Story
Leadership & Advisors
Pillar News
Distribution Partners
Strategic Partnership
Technology
Products
Portfolio Overview
IVD Products
Solid Tumor Tissue
Liquid Biopsy
Heme
BRCA, HRD, Methylation
Inherited Disease
Pharma
Resources
Resource Overview
Webinars and Presentations
Publications
Posters
Contact
Careers
Investors
Company
Our Story
Leadership & Advisors
Pillar News
Distribution Partners
Strategic Partnership
Technology
Products
Portfolio Overview
IVD Products
Solid Tumor Tissue
Liquid Biopsy
Heme
BRCA, HRD, Methylation
Inherited Disease
Pharma
Resources
Resource Overview
Webinars and Presentations
Publications
Posters
Contact
Careers
Investors
Publications
Validation and Performance of Quantitative BRCA1 and RAD51C Promoter Hypermethylation Testing in Breast and Ovarian Cancers
Publication Source:
The Journal of Molecular Diagnostics
TBC
Tags
Resource Topic
BRCA
|
HRD
|
Methylation
Year
2025